Patent for Making Combination Chemotherapy Work Better
All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. “S-Phase cytotoxics, such as Pfizer’s irinotecan or Eli Lilly’s gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy,” explains
Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. “With less than one third of cancer cells in the S-Phase, today’s cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, while simultaneously preventing tumor regrowth between administrations of S-Phase cytotoxic, is required under established principles of chemotherapy for curative outcome. Drugs capable of doing both already exist for many cancers, providing the potential for an immediate advance in cancer treatment under our protocols,” according to Mr. Zamoyski.
More information is available at www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.
SOURCE NexGen Biomedical, Inc.